Top 50 Global Biopharma Companies Dealmaking Reviewed in New Topical Report Published at MarketPublishers.com

• 

http://marketpublishers.com/

London, UK (PRWEB) June 21, 2012

What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subscontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? The answers to all these questions and many more can be found in the research report.

New research report “Partnering Agreements with Bigpharma 2012” worked out by CurrentPartnering has been recently published by Market Publishers Ltd.

Report Details:

Title: Partnering Agreements with Bigpharma 2012
Published: June, 2012
Pages: 957
Price: US$ 2,695.00
http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/healthcare_equipment_services/partnering_agreements_with_bigpharma_2012.html

The research report is aimed to provide an in-depth understanding of the dealmaking interests and activity of the top fifty biopharma companies the world over.

Report Scope:

•     detailed company profiles for each of the top 50 bigpharma companies, including:
•     partnering interests and indications;
•     partnering activity since 2005 – number of deals per year;
•     partner companies since 2005;
•     partnering activity since 2005 by:
•     partner company;
•     deal type;
•     industry sector;
•     stage of development;
•     technology type;
•     therapy area;
•     over 300 charts showing the dealmaking activity of each company since 2005;
•     tools to enable effective and efficient preparation for partnering negotiation with bigpharma;
•     3,000 partnering deals as recorded at Current Agreement, together with contract documents if available;
•     top M&A and partnering deals by value 2005-2012;
•     comprehensive access to available contract documents for each of the fifty bigpharma companies.

Report Contents:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Bigpharma Top 50 Dealmaking Activity

2.1. Introduction
2.2. Bigpharma partnering over the years
2.4. Bigpharma partnering by deal type
2.5. Bigpharma partnering industry sector
2.6. Bigpharma partnering by stage of development
2.7. Bigpharma partnering by technology type
2.8. Bigpharma partnering by therapy area
2.9. Bigpharma M&A over the years

Chapter 3 - Top Bigpharma Deals By Value

3.1. Introduction
3.2. Bigpharma partnering
3.3. Bigpharma M&A

Chapter 4 - Submitting Opportunities to Bigpharma

4.1. How to submit an opportunity
4.2. Opportunity submission template
4.3. Sending emails
4.4. Face to face at partnering events
4.5. Online submission forms

Chapter 5 - Forthcoming Bigpharma Partnering Events

5.1. Forthcoming events

Chapter 6 - Bigpharma Company Profiles

6.1. Introduction
6.2. Field definitions
6.3. Company profiles
Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
...

More new research reports by the publisher can be found at CurrentPartnering page.

PDF Print